Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based interferon-β gene therapy and cisplatin in a mouse melanoma model

Cytotherapy

Volumn 13, Issue 8, 2011, Pages 944-955

  Seo, Kyoung Won ^a   Lee, Hee Woo ^a   Oh, Ye In ^a   Ahn, Jin Ok ^a   Koh, Ye Rin ^a   Oh, Seung Hyun ^b   Kang, Sung Keun ^c   Youn, Hwa Young ^a  

^a Seoul National University   (South Korea)

^b National Cancer Center   (South Korea)

^c Stem Cell Research Center   (South Korea)

Author keywords

adipose tissue derived mesenchymal stromal cells; canine; cell vehicle; interferon ; melanoma

Indexed keywords

BETA INTERFERON; CISPLATIN; LENTIVIRUS VECTOR;

ADIPOSE TISSUE CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; MELANOMA; MESENCHYME CELL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STROMA CELL; SURVIVAL TIME; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM;

EID: 80051903684     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.584864     Document Type: Article

References (60)

1. Weatherall DJ. Scope and limitations of gene therapy. Br Med Bull. 1995;51:1-11.
2. Dwyer RM, Kerin MJ. Mesenchymal stem cells (MSCs) and cancer: tumour specifi c delivery vehicles or therapeutic targets? Hum Gene Ther. 2010;21(11):1506-12.
3. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002;62:3603-8. (Pubitemid 34728832)
4. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005;65: 3307-18. (Pubitemid 40524615)
5. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeteddelivery vehicles for anticancer agents. J Natl Cancer Inst. 2004;96:1593-603. (Pubitemid 39534883)
6. Pereboeva L, Curiel DT. Cellular vehicles for cancer gene therapy: current status and future potential. BioDrugs. 2004; 18:361-85. (Pubitemid 40023611)
7. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650-9. (Pubitemid 17052899)
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. (Pubitemid 30046295)
9. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24: 1294-301. (Pubitemid 44464698)
10. Oedayrajsingh-Varma MJ, van Ham SM, Knippenberg M, Helder MN, Klein-Nulend J, Schouten TE, et al. Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure. Cytotherapy. 2006;8:166-77. (Pubitemid 43675203)
11. Hui JH, Li L, Teo YH, Ouyang HW, Lee EH. Comparative study of the ability of mesenchymal stem cells derived from bone marrow, periosteum, and adipose tissue in treatment of partial growth arrest in rabbit. Tissue Eng. 2005; 11:904-12. (Pubitemid 40960793)
12. Wigginton JM, Wiltrout RH. IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert Opin Biol Ther. 2002;2:513-24. (Pubitemid 34716734)
13. Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, et al. IFN-alpha enhances peptide vaccine-induced CD8- T cell numbers, effector function, and antitumor activity. J Immunol. 2009;182:7398-407.
14. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996;14:2666-73. (Pubitemid 26329650)
15. Spiegel RJ. The alpha interferons: clinical overview. Semin Oncol. 1987;14:1-12. (Pubitemid 17127640)
16. Einhorn S, Grander D. Why do so many cancer patients fail to respond to interferon therapy? J Interferon Cytokine Res. 1996;16:275-81. (Pubitemid 26132339)
17. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6:34-55. (Pubitemid 32155814)
18. Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol. 1984;2:336-52. (Pubitemid 14107002)
19. Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res. 2001;7:1821-31. (Pubitemid 32708654)
20. Chen Q, Gong B, Mahmoud-Ahmed AS, Zhou A, Hsi ED, Hussein M, et al. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood. 2001;98:2183-92.
21. Morrison BH, Bauer JA, Kalvakolanu DV, Lindner DJ. Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells. J Biol Chem. 2001;276:24965-70.
22. Horikoshi T, Fukuzawa K, Hanada N, Ezoe K, Eguchi H, Hamaoka S, et al. In vitro comparative study of the antitumor effects of human interferon-alpha, beta and gamma on the growth and invasive potential of human melanoma cells. J Dermatol. 1995;22:631-6.
23. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher effi cacy of interferon beta. J Natl Cancer Inst. 1992;84:1185-90.
24. Taylor KL, Leaman DW, Grane R, Mechti N, Borden EC, Lindner DJ. Identifi cation of interferon-beta-stimulated genes that inhibit angiogenesis in vitro. J Interferon Cytokine Res. 2008;28:733-40. (Pubitemid 352773930)
25. Rachakatla RS, Pyle MM, Ayuzawa R, Edwards SM, Marini FC, Weiss ML, et al. Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fl uorouracil signifi cantly reduces growth of metastatic human breast cancer in SCID mouse lungs. Cancer Invest. 2008;26:662-70.
26. Rachakatla RS, Marini F, Weiss ML, Tamura M, Troyer D. Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther. 2007;14:828-35. (Pubitemid 47402382)
27. Chirino YI, Hernandez-Pando R, Pedraza-Chaverri J.Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC Pharmacol. 2004;4:20.
28. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-91. (Pubitemid 44343542)
29. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351-60. (Pubitemid 38101630)
30. Balkwill F, Taylor-Papadimitriou J. Interferon affects both G1 and S- G2 in cells stimulated from quiescence to growth. Nature. 1978;274:798-800.
31. Kopf J, Hanson C, Delle U, Weimarck A, Stierner U. Action of interferon alpha and beta on four human melanoma cell lines in vitro. Anticancer Res. 1996;16:791-8. (Pubitemid 26182011)
32. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987;47:5155-61. (Pubitemid 17146488)
33. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998; 67:227-64. (Pubitemid 28411130)
34. Gibson DF, Johnson DA, Goldstein D, Langan-Fahey SM, Borden EC, Jordan VC. Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse. Breast Cancer Res Treat. 1993;25:141-50. (Pubitemid 23170613)
35. Fuertes MA, Alonso C, Perez JM. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev. 2003;103:645-62.
36. Li D, Ronson B, Guo M, Liu S, Bishop JS, Van Echo DA, et al. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor effi cacy in combination with cisplatin for head and neck squamous cell cancer. Cancer Res. 2002;62:4023-8. (Pubitemid 34791069)
37. B alkwill FR, Mowshowitz S, Seilman SS, Moodie EM, Griffi n DB, Fantes KH, et al. Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug-metabolizing enzymes. Cancer Res. 1984;44:5249-55. (Pubitemid 15204496)
38. Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA. 1988;260:974-6.
39. Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther. 2008;15:739-52. (Pubitemid 351627357)
40. Pisati F, Belicchi M, Acerbi F, Marchesi C, Giussani C, Gavina M, et al. Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models. Cancer Res. 2007;67:3054-63. (Pubitemid 46724842)
41. Maestroni GJ, Hertens E, Galli P. Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life Sci. 1999;55:663-7. (Pubitemid 29221598)
42. Ohlsson LB, Varas L, Kjellman C, Edvardsen K, Lindvall M. Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Exp Mol Pathol. 2003;75:248-55. (Pubitemid 37373711)
43. Lu YR, Yuan Y, Wang XJ, Wei LL, Chen YN, Cong C, et al. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther. 2008;7:245-51. (Pubitemid 351590431)
44. Zhu W, Xu W, Jiang R, Qian H, Chen M, Hu J, et al. Mesenchymal stem cells derived from bone marrow favortumor cell growth in vivo. Exp Mol Pathol. 2006;80: 267-74.
45. Kyriakou CA, Yong KL, Benjamin R, Pizzey A, Dogan A, Singh N, et al. Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt ' s lymphoma in a murine model. J Gene Med. 2006;8:253-64.
46. Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin- 6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells. 2006;24:986-91. (Pubitemid 44464731)
47. Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia. 2007;21:304-10. (Pubitemid 46158124)
48. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira, II, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi ' s sarcoma. J Exp Med. 2006;203:1235-47. (Pubitemid 43736593)
49. Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res. 1996;16:759-64. (Pubitemid 26389112)
50. Elzaouk L, Moelling K, Pavlovic J. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol. 2006;15:865-74. (Pubitemid 44473325)
51. Keating A. How do mesenchymal stromal cells suppress T cells? Cell Stem Cell. 2008;2:106-8. (Pubitemid 351168716)
52. Keating A. Mesenchymal stromal cells. Curr Opin Hematol. 2006;13:419-25. (Pubitemid 44607442)
53. Marigo I, Dolcetti L, Serafi ni P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222: 162-79. (Pubitemid 351430364)
54. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105:1815-22. (Pubitemid 40223708)
55. Nasef A, Mathieu N, Chapel A, Frick J, Francois S, Mazurier C, et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation. 2007;84:231-7. (Pubitemid 47205757)
56. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell - natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 2006;107:1484-90. (Pubitemid 43242385)
57. Chen JL, Guo ZK, Xu C, Li YH, Hou CM, Mao N, et al. [Mesenchymal stem cells suppress allogeneic T cell responses by secretion of TGF-beta1]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2002;10:285-8.
58. Rodriguez AM, Pisani D, Dechesne CA, Turc-Carel C, Kurzenne JY, Wdziekonski B, et al. Transplantation of a multipotent cell population from human adipose tissue induces dystrophin expression in the immunocompetent mdx mouse. J Exp Med. 2005;201:1397-405. (Pubitemid 40664084)
59. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11-20. (Pubitemid 38019084)
60. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31:890-6. (Pubitemid 37211373)